Immix Biopharma, Inc. IMMX

Rank #2401 · Nasdaq · $0.4B market cap

Audited by Crowe LLP, no going-concern flag in the latest filing.

Score

20.7

P/E

-19.3

P/B

25.79

ROE

-133.4%

Op. Margin

–%

Debt Ratio

60%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆

Poor

P/E -19.3x, P/B 25.79x. Ranks in the top 84% of the universe.

Profitability ★☆☆☆☆

Poor

ROE -133.4%. Ranks in the top 96% of the universe.

Safety ★★★★☆

Good

Debt ratio 60%. Ranks in the top 26% of the universe.

Growth –

No data

Not enough historical filings to compute year-over-year growth yet.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

FY	Revenue	Op. Income	Net Income	Equity	Op. Margin%	Debt%
2021	–	$-0.0B	$-0.0B	$-0.0B	–	-145
2022	–	$-0.0B	$-0.0B	$-0.0B	–	-4
2023	–	$-0.0B	$-0.0B	$0.0B	–	13
2024	–	$-0.0B	$-0.0B	$0.0B	–	23
2025	–	$-0.0B	$-0.0B	$0.0B	–	60